M e di c a r e h a s u n d e r g o n e a dramatic change, as provided for in the Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003. As of January 2006, for the first time all Medicare beneficiaries have the option to purchase Medicare-subsidized outpatient prescription drug coverage. This new benefit is the first universally available one financed by Medicare that is provided exclusively through private insurers. 1 Three main types of private plans contract with Medicare to provide this coverage: local Medicare Advantage (MA) managed care plans, which are the successors to the Medicare+Choice plans; regional preferred provider organizations (PPOs) operating under the MA program; and regional stand-alone prescription drug plans (PDPs). 2 The diversity of plan types, number of plans, and variations in cost sharing and formulary design have been reported in the media to be sources of confusion among beneficiaries. 3 Local MA plans, which contract with Medicare county by county, are not new. Local managed care plans, generally health maintenance organizations (HMOs), have been part of Medicare since 1982. Until January 2006, such plans were the only way beneficiaries could obtain Medicare coverage for outpatient prescription drugs. 4 Although most local MA plans will provide drug benefits, they are expected to operate primarily in urban areas, as they have in the past. 5 Some PPOs have participated in Medicare in the recent past, mostly as part of a demonstration. 6 One feature of the new regional MA PPOs is the requirement that their service areas be defined in terms of twenty-six multistate regions that include rural areas. This constraint puts regional PPOs at a competitive disadvantage relative to local MA plans, which is offset, although perhaps only partly, by increased regional PPO payments, regional payment adjustments, and a temporary MA Stabilization Fund. 7 Regional PPOs have entered twenty-one MA regions in 2006 and must offer beneficiaries a basic drug plan.
Stand-alone PDPs are a new source of outpatient prescription drug coverage in Medicare and the only available source for some beneficiaries. Unlike local MA plans and regional PPOs, PDPs offer drug coverage only, not comprehensive health insurance. Beneficiaries enrolling in a PDP rely on traditional fee-for-service (FFS) Medicare for coverage of nondrug services. Like regional MA PPOs, the stand-alone PDPs are regional plans with service areas defined in terms of thirty-four PDP regions. 8 Little is known about PDPs, because they did not exist before January 2006.
This study, based on data from the Centers for Medicare and Medicaid Services (CMS), analyzes the availability, costs, and benefits of PDPs participating in 2006 in the context of other Medicare drug plan options. We analyze plan characteristics, which can appear different to beneficiaries depending on their eligibility for low-income subsidies from Medicare. Certain low-income beneficiaries and those dually eligible for Medicaid or receiving Supplemental Security Income (SSI) qualify for full or partial premium subsidies and reduced cost sharing. Also, those who are eligible for subsidies but do not select a drug plan will be automatically enrolled in one by the CMS.
Study Data And Methods
Data on characteristics of all local MA and regional MA PPO drug plans and all standalone PDPs were obtained from the CMS Web site in March 2006. 9 Data elements include insurer, plan name, premium, deductible, gap coverage, percentage of the top 100 drugs covered, percentage of the top 100 drugs requiring prior authorization, and percentage of the top 100 drugs with a copayment below $20. 10 Comprehensive data on formularies for Medicare drug plans were not available at the time of this study. However, the CMS has placed an interactive tool on its Medicare Web site, http://www.medicare.gov, that allows users to see which drugs are covered by each plan's formulary. We developed a protocol that used this Formulary Finder tool to query the underlying formulary database. For tractability, we focused on specific, frequently prescribed, brand-name drugs and on a restricted set of stand-alone PDPs available nationally (or nearly so). We queried the Formulary Finder with twelve brand-name drugs, selected because they are among the thirty most commonly prescribed to the elderly participating in the Pennsylvania Pharmaceutical Assistance Contract for the Elderly and also among the fifty with largest national sales volume. 11 For the twelve selected drugs, we used the Formulary Finder to learn whether or not the drug was covered and, if it was, its formulary tier. 12 We did this for fifteen specific plans, selected because they (1) are offered by large insurers, (2) are offered everywhere (or nearly so) in the country, and (3) have nearly constant copayment amounts across their service areas. 13 For convenience, we refer to these plans as "national plans" and note that our list of national plans differs from those publicized by other organizations. 14 
Study Results
n MA drug plans. There are two types of MA drug plans: those offered by local MA plans and those offered by regional PPOs. Some insurers offering an MA plan of either type offer multiple drug coverage products: a basic plan and one or more enhanced plans with higher premiums and more generous coverage. For example, in Cook County, Illinois, Humana offers four local drug plans: two through HMOs (a basic one with zero monthly drug premium and an enhanced one with a $26 monthly drug premium), one through a local PPO ($31 monthly drug premium), and one through a private FFS plan ($23 monthly drug premium). All four plans have a zero drug deductible and are identical in nearly all available measures of cost sharing and formulary generosity. Some small differences exist across the plans in copayments for some tiers, the interpretation of which is diffi-cult without detailed formulary data (not available for this study). 15 The Humana PPO is unique among the four in covering generic drugs in the gap. Note, however, that gap coverage among local MA drug plans is uncommon; only 14 percent of plans offer it.
In earlier work, we forecast that regional PPOs would not participate in large numbers. 16 Although they are fewer in number than stand-alone PDPs and local MA plans, regional PPOs are present in all but five MA regions (Exhibit 1). The average MA region has 2.4 regional PPO offerings, all of which offer at least a basic drug benefit (62 offers in 26 MA regions), while the average county has 3.6 local MA drug plan offerings (11,646 offers in 3,274 counties) and the average PDP region has 42 stand-alone PDP offerings (1,429 offers in 34 PDP regions). 17 The average drug premium for regional PPO drug plans is $22 per month. About onethird have a $250 annual deductible; twothirds have zero deductible. The average drug premium for local MA drug plans is $19 per month. Additionally, compared with regional PPOs, a higher proportion of local MA drug plans (three-quarters) have a zero deductible for drugs. Almost all of the remaining onequarter of local MA drug plans have a $250 annual deductible.
n Stand-alone PDPs. Relative to regional PPOs, stand-alone PDPs are available in larger numbers. All PDP regions have at least twenty-seven PDP options, and a few have more than fifty. On average, the monthly drug premium for a PDP is $37-well above the averages for local MA drug plans and regional PPOs. A smaller proportion of PDPs (about half) have zero deductible for drugs, relative to local MA plans and regional PPOs. About 34 percent of stand-alone PDPs have a $250 annual deductible, approximately the same as for regional PPOs but a higher percentage than for local MA drug plans. Seven percent have a $100 deductible, and 1 percent have other deductible levels ($50, $150, or $175).
Like the local and regional MA plans described previously, some insurers offer multiple stand-alone PDPs in the same region. Typically one product is a high-deductible plan, and one or more are low-deductible plans. Low-deductible plans outnumber highdeductible plans nationally and in every region by about two to one (Exhibit 2). The national average monthly premium for low-deductible plans is $10 higher than that for high-deductible plans.
For both deductible types and within every region, there is much variation in premiums, with the maximum premium often many times higher than the minimum premium. For example, in region 25 the maximum premium for low-deductible PDPs is $100 per month, or twenty times that of the minimum premium H e a l t h T r a c k i n g for low-deductible plans in the same region ($5 per month). Region 17 is more typical, where the maximum premium for highdeductible PDPs is $38 per month, compared with the minimum premium for high-deductible plans ($13 per month). Despite this within-region premium variability, the mean premium across regions does not vary greatly for either deductible type (Exhibit 2). The mean percentage of the top 100 drugs covered is also nearly constant across the PDP regions: about 93 percent for both low-and high-deductible plans (data not shown). Some important differences between lowand high-deductible stand-alone PDPs are not shown in Exhibit 2. Low-deductible plans charge a copayment under $20 for fewer of the top 100 drugs than high-deductible plans do: an average of fifty-eight of the top 100 drugs in low-deductible plans versus an average of seventy-two in high-deductible plans. But more low-deductible plans (23 percent) than highdeductible plans (0 percent) offer gap coverage. Plans with any gap coverage charge relatively high premiums: $50 per month on average-about $10 per month more than the average low-deductible plan premium. Those with generic and brand-name (as opposed to just generic) gap coverage charge the highest monthly premiums: $61 on average, or $20 more than that of the average low-deductible plan.
M a r k e t W a t c h H E A LT H A F F A I R S~We b E x c l u s i v e
Thus, although there is considerable premium variation within each region, some broad characteristics of PDP offerings (for example, total number of plans, ratio of low-to high-deductible plans, mean premiums, number of top 100 drugs covered) vary little across regions. There are also substantial differences in characteristics between low-and highdeductible plans. On average, plans compensate for a lower deductible by charging both a higher premium and higher copayments. H e a l t h T r a c k i n g single insurer in nearly every state and have nearly constant benefits.) All but one insurer (UnitedHealthcare) offers multiple plans, typically one high-deductible plan and two lowdeductible plans. One of the low-deductible plans has more generous coverage for a higher premium: either more generous coverage of the most popular drugs or provision of some coverage in the gap, or both. For each national plan and each region of operation, monthly premiums vary (Exhibit 3). For some plans, the ratio between maximum and minimum premium is considerable-a factor of 8 for Humana's PDP Standard (although this is an outlier and on a small base of $2)-while for most plans, the ratio is well under 2. The minimum and maximum values are driven by benefit generosity and by regional prices and competition. Mean premiums vary across plans in accordance with the generosity of benefits.
One measure of generosity is the deductible. All plans in Exhibit 3 offer either a zero or a $250 deductible. Among the same insurer's offerings, low-deductible plans have a higher premium. Another measure of generosity is degree of coverage of popular drugs. Some higher-premium plans cover a larger share of popular drugs, cover more without requiring prior approval, or cover more at lower cost. Finally, gap coverage comes at a higher price, particularly for brand-name gap coverage. Only one-third of these national plans offer gap coverage, and only one, Humana's PDP Complete, offers gap coverage of brand-name drugs. This one-third offering gap coverage is a much higher percentage than is true for all stand-alone PDPs (15 percent) and local MA drug plans (14 percent). Gap coverage for generic drugs only is offered by five or six standalone PDPs in all but one region (region 8, NC), where eight PDPs offer gap coverage for generics. Gap coverage for brand-name drugs is more rare, offered by only one or two PDPs in all but three regions (data not shown). No brand-name gap coverage is available in regions 1, 33, and 34.
To examine the generosity of the national PDPs in greater detail, we checked the availability of and cost sharing for twelve of the most popular brand-name drugs among the elderly (Exhibit 4). Exhibit 5 provides costsharing details for each of the popular drugs listed in Exhibit 4 and for each national PDP listed in Exhibit 3. Few plans offer coverage for all twelve of the drugs. For insurers offering multiple plans, if only one plan covers all twelve, it is the highest-premium plan (for example, Aetna's Medicare Rx Premier and Unicare's Medicare Rx Rewards Premier). Celexa (drug A in Exhibit 5) is the least likely of the twelve drugs to be covered, and when it is covered, it has the highest copayment. Products offered by WellCare cover the fewest of these twelve drugs, while all of Humana's products cover all of them, although with relatively high cost sharing for some. UnitedHealthcare's AARP MedicareRx, which covers all but Celexa, and Aetna's Medicare Rx Premier, which covers all twelve, have relatively low mean copayments.
Discussion
This paper places the stand-alone PDP in the context of local and regional variants of more familiar types of Medicare plans. Regional PPOs are vastly outnumbered by regional stand-alone PDPs. Where they exist, local MA plans offer lower premiums for outpatient drug coverage relative to regional stand-alone PDPs or regional PPO drug plans.
Broad PDP characteristics do not vary much from region to region. However, within H e a l t h T r a c k i n g regions, characteristics vary widely, which has been reported in the media as a source of confusion for beneficiaries. The complexity is reduced by focusing only on national plans offered by large insurers. 18 Each of the large insurers we examined offered up to three plans: a high-deductible ($250) plan with the lowest premium, a zero-deductible plan with a midrange premium, and a zero-deductible plan with the best coverage and highest premium. These national plans constitute a basic set of plans available to nearly all beneficiaries. Even when attention is restricted to national plans, beneficiaries have meaningful choices, with much variation in cost and generosity. Some plans, like those offered by WellCare, have both restrictive formularies and high premiums relative to other plans like UnitedHealthcare's AARP MedicareRx. Of course, the importance of formulary restrictions will be different for each beneficiary, depending on which drugs he or she expects to use. In addition, beneficiaries face different out-of-pocket cost-sharing liability, depending on whether or not they qualify for lowincome subsidies. Among PDPs, a small minority offer coverage in the gap (or "doughnut hole"). Only one national plan, Humana's PDP Complete, offers brand-name gap coverage. Humana has adopted a strategy unique among national plans, one that exposes it to risk of adverse selection but that also holds the potential to capture substantial market share. Whether this strategy will prove to be profitable ought to become evident during 2006.
More generally, whether the PDP sector receives either favorable or adverse selection will be key to the stability of this component of the Medicare prescription drug program. Recent work suggests that stand-alone PDPs will experience substantial adverse selection but will nonetheless remain stable, as long as subsidies are not cut too deeply. 19 The temptation by lawmakers to rein in subsidy spending is already evident. For example, late in 2005 a Senate budget reconciliation bill (S. 1932) included a provision to phase out a fund created by MMA to encourage insurers to offer prescription drug coverage. 20 Some plans could make up for a loss in government payments by increasing their deductibles or copayments or by changing formularies. Plans already offering the statutory minimum benefit and restrictive formularies would have to increase premiums to make up the loss. If this happens, beneficiaries expecting to have low drug usage might judge the increased premium not worth the benefit and decline coverage, potentially destabilizing these plans.
T h e l an d s c a p e o f p r i vat e Medicare plans is dynamic. In addition to the familiar plan entries, exits, and service-area refinements, as of 2008 the moratorium on new local PPO entry written into MMA will be lifted. It will be interesting to see how regional drug plans, both PPOs and PDPs, respond when this change takes place.
